Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.

Emerging role of lipoprotein(a) lowering for CVD risk reduction

10 Oct 2018

Pathophysiological, epidemiological and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). [J Am Coll Cardiol 2017;69:692-711]

According to Professor Sotirios Tsimikas from the University of California San Diego, US, the estimated global population with elevated Lp(a) >50 mg/dL is 1.43 billion, and the associated risk is consistent across a broad spectrum of patients, including those with LDL-cholesterol <70 mg/dL. Hence, clinical guidelines now recommend considering Lp(a) screening and treatment for high-risk individuals, such as those with familial hypercholesterolaemia, or those with recurrent CVD despite optimal lipid lowering. [J Am Coll Cardiol 2018;71:177-192; Eur Heart J 2016;37:2999-3058]

Current therapies such as mipomersen and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower Lp(a) by 20–30 percent, but are not indicated for Lp(a) lowering as such.  Emerging RNA-targeted therapeutics are the first to be specifically evaluated in randomized trials of Lp(a) lowering in individuals with high baseline Lp(a).

“Results are promising. For instance, the antisense oligonucleotide [ASO] IONIS-APO(a) produced dose-dependent reductions in Lp(a) levels of around 80 percent, with no apparent safety concerns,” reported Tsimikas. [Lancet 2016;388:2239-2253] Another ASO, AKCEA-APO(a), is now under phase I trial. [https://clinicaltrials.gov/ct2/show/NCT03070782]

“Specific therapies currently in clinical development will allow us to test the Lp(a) hypothesis that lowering elevated Lp(a) levels will lead to improved clinical outcomes,” he concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.